136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)

Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation

Content provided by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist, David Brühlmann - CMC Development Leader, Biotech C-level Advisor, and Business Strategist or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

2M ago 13:28

MP3•Episode home

Send us a text

Sickle cell disease affects thousands with severe daily pain. While FDA-approved gene therapies exist, their $2.2 million cost per treatment makes them largely inaccessible.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann explores five key challenges facing the bioprocessing industry in making these therapies more accessible:

Moving Away from Platform Technologies

Traditional bioprocessing relies on platform technologies for antibody production. However, new therapies require more flexible, adaptable systems that can accommodate novel modalities.

Increased Personalization and Smaller Batch Sizes

Personalized medicine, especially autologous cell therapy, demands highly customized approaches. With batch sizes of one patient, traditional automation becomes challenging, requiring new methodologies.

Cultivating Sensitive Cells

Modern cell types need gentler handling than traditional CHO cells. Companies are developing innovative bioreactor technologies, from acoustic wave systems to stress-free cultivation methods.

The Cell as the Product

Cell-based products are billion times more complex than antibodies, requiring sophisticated production, monitoring, and quality control processes.

Accessibility and Cost Challenges

High treatment costs remain the biggest barrier. For example, only 21,000 of 900,000 eligible patients have received CAR T cell therapy due to financial constraints.

Moving Forward

Industry leaders across academia and pharma are collaborating to overcome these challenges through innovation and cost reduction. Every improvement brings us closer to making these treatments accessible to more patients.

Join us on the Smart Biotech Scientist Podcast as we explore innovative solutions to these challenges.

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

157 episodes

#Science #Biology #Cell Culture Technology Innovation Aficionado #David Brühlmann: Biotech Entrepreneur #Bioprocess #Biotech #Cell Culture #Development #CMC #Manufacturing #Scale #Technology #Scientists #Innovation